Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MICTLAN: Dolutegravir vs Bictegravir in ART-naïve HIV patients
NCT06629480Phase 4Completed
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Jun 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir, dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Instituto Mexicano del Seguro Social. Started Jun 2021; status: completed.
02
Drugs
bictegravirdolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06629480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629480.